Novo Nordisk acquires all shares of Biocorp

Novo Nordisk has completed the acquisition of 100% of the shares of Biocorp, a France-based drug delivery device maker. The deal values Biocorp at approximately $164.5 million (€154 million).

“This is a huge opportunity for all our teams since we all together are 'united by differences, powered by innovation.'”drugdeliverybusiness.com

• 1 source
• drugdeliverybusiness.comNovo Nordisk buys all shares of drug delivery device maker BiocorpSean WhooleyOct 11, 2023

Summarized from public sources; check the original articles before acting on it.